MGF: Muscle-Growth Claims, Reported Doses and PEG-MGF
Muscle growth and post-workout claims
People look into MGF hoping to grow a lagging muscle, recover after hard training or help an injury. Controlled human studies have not established those results for injected synthetic MGF.
Plain MGF and PEG-MGF are different materials. Research on the body's own training response does not validate a product's dose or post-workout schedule.
One name can mean different things
Inside muscle The body's response to training
Studies can measure repair-related signals.
A test of an injected product
Manufactured fragment
PEG-modified material
Reported amounts and post-workout timing
A Nova Labs supplier sheet lists the following example. It does not establish a validated route-specific regimen or prove that post-workout timing improves gains.
200 mcg
Reported amount
An amount of material, not a syringe marking.
3× weekly
After workouts
The supplier's timing description, not an outcome-trial result.
Not specified
Course length
No validated duration follows from that row.
| Question | What the evidence can support |
|---|---|
| Does post-workout timing improve gains? | The supplier’s timing is not established by a human outcome trial |
| Does injecting a lagging muscle target growth there? | No reliable human site-specific benefit established |
| How long should a cycle last? | No verified clinical recovery cycle follows from the cell studies |
An assumed short half-life does not establish a need to inject immediately after training.
What MGF actually is
The IGF1 gene can produce different precursor forms through alternative splicing. In human muscle research, the Ec form is often called mechano growth factor. These precursor forms share the mature IGF-1 sequence but differ in their additional E-peptide regions.
Synthetic “MGF” commonly refers to a short sequence from an E-region, rather than the complete IGF-1 precursor or mature IGF-1 hormone. The sequence and modification matter: a vendor name alone cannot identify which substance a paper tested.
Two meanings of MGF
| Distinction | Muscle biology | Synthetic peptide |
|---|---|---|
| What is measured? | IGF1 splice-form expression or precursor biology | A manufactured fragment with a defined sequence |
| Typical experiment | Muscle response to loading or injury | Effects on cultured cells or in animals |
| What would need separate proof? | How the precursor is processed in living tissue | Human absorption, safety and clinical benefit after administration |
How it works in muscle repair
A frequently cited 2002 experiment found that an MGF E-domain peptide increased proliferation of cultured muscle precursor cells while inhibiting their terminal differentiation. That is a useful clue about cell behavior. It is not a human trial of muscle gain, and making cells proliferate is not the same outcome as restoring a functioning muscle. Yang and Goldspink
A later independent cell experiment did not reproduce an activating response to native or stabilized MGF peptides, despite a clear response to IGF-1. Even the laboratory findings are not uniformly positive.
The distinction also explains why “MGF activates repair” is too broad: processing, receptor effects, tissue context and the measured endpoint all matter. A subsequent scholarly analysis specifically questioned whether the short synthetic fragment had been demonstrated as a naturally liberated peptide. Mechanistic analysis
The half-life problem (and PEG-MGF)
A dependable human injection half-life was not established by the sources reviewed. The previous 30-minute half-life and 50% bioavailability should not be treated as measured human PK. A model built from assumed rates can illustrate mathematics, but cannot supply the missing measurements.
PEG-MGF adds a polyethylene glycol modification intended to change handling and persistence. That changes the material; it does not automatically establish a particular human half-life, dose equivalence or improved healing. See the MGF page for the model’s current scope.
The evidence is mostly preclinical
The central gap is a controlled human study of an identified product, route and meaningful outcome. Muscle gene-expression experiments and cell-culture results do not fill it. Nor does proximity to an injury establish that an injected substance will act only at that site.
WADA status
The WADA Prohibited List includes mechano growth factors among prohibited growth factors. Prohibited status does not prove clinical effectiveness. Testing methods and detection times are separate questions from elimination half-life.
Where this leaves things
For the reader’s actual goal—more muscle or a return to training—the missing link is a demonstrated improvement in strength, muscle size or recovery time. A cell response or marketed post-workout schedule cannot supply that result. Keep plain MGF and PEG-MGF separate when comparing any reported experience.
Frequently asked questions
Is MGF the same as IGF-1? The name is associated with an IGF-1 splice form, but a synthetic E-fragment is not mature IGF-1.
Does PEG-MGF have a proven longer human half-life? A chemical rationale for longer persistence is not a measured human PK result for the supplied product.
Do human muscle studies prove injectable MGF works? No. Measuring a response inside muscle is different from testing an injected synthetic fragment.
Sources
Research scope and terminology
- Yang and Goldspink, 2002: original cell-model study; PubMed indexes an erratum.
- Matheny et al., 2010: analysis of the precursor/fragment hypothesis and unobserved processing step.
- WADA current Prohibited List: sport classification, not efficacy evidence.
Related compounds & model context
Article citations are linked in the text. Related catalog entries have separate model inputs and source notes, which may include unverified estimates. See our methodology for model assumptions and limitations.